Viking Therapeutics, Inc.

VKTX

Viking Therapeutics, Inc.

VKTX

Insider Sentiment (TTM):

Last Purchase:2026-03-10Last Sale:2026-01-05Shares Purchased (TTM):4,475Shares Sold (TTM):476,090

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:72,178,562Shares Outstanding:115,568,078Institutional Ownership Pct.:62.46%

Earnings Market Reaction:

Filing Date:2026-07-29Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	126	118	166	100	34	38	27	50	44	196	56	37
Available For Sale Securities Debt Securities Curr…	376	485	540	614	774	814	876	880	898	767	307	339
Prepaid Expense And Other Assets Current	1	1	2	2	3	1	1	2	0	1	3	1
Assets Current	518	608	716	739	827	866	907	937	946	966	367	381
Operating Lease Right Of Use Asset	4	0	0	1	1	1	1	1	1	1	1	1
Restricted Cash Noncurrent	0	-	-	-	-	-	-	-	-	-	-	-
Deposits Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	522	608	716	739	828	867	908	938	947	968	368	383
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	69	67	53	4	5	8	10	0	11	5	8	6
Other Accrued Liabilities Current	40	39	23	21	26	11	17	25	14	27	11	7
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Liabilities Current	110	106	77	26	32	20	27	26	25	33	19	13
Operating Lease Liability Noncurrent	4	-	0	0	0	1	1	1	1	1	1	1
Liabilities Noncurrent	4	-	0	0	0	1	1	1	1	1	1	1
Liabilities	114	106	77	26	32	20	28	26	26	34	20	14
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Treasury Stock Value	-	-	0	0	0	0	0	0	0	0	-7	-7
Additional Paid In Capital Common Stock	1,543	1,509	1,486	1,403	1,395	1,381	1,369	1,362	1,351	1,341	734	729
Retained Earnings Accumulated Deficit	-1,134	-1,006	-848	-690	-599	-534	-488	-452	-428	-405	-378	-353
Accumulated Other Comprehensive Income Loss Availa…	-1	-1	0	0	-0	-0	-1	2	-2	-2	-0	-1
Stockholders Equity	408	502	639	713	795	847	880	911	921	934	348	368
Liabilities And Stockholders Equity	522	608	716	739	828	867	908	938	947	968	368	383
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	117	116	115	112	112	112	112	111	111	110	100	100
Shares Outstanding	117	116	115	112	112	112	112	111	111	110	100	100
Treasury Stock Common Shares	-	-	0	0	0	0	0	0	0	0	2	2

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-0.93%	-2.57%	18.92%	-	-	-	-	-	-	-	-	-
2025	10.80%	1.64%	21.24%	19.85%	-25.72%	0.48%	15.30%	9.32%	-5.69%	15.52%	21.89%	5.08%
2024	-2.70%	-24.46%	-16.96%	12.50%	32.37%	30.61%	-17.90%	-22.12%	-34.91%	4.06%	-13.95%	2.19%
2023	-	-	-	-	-	-	5.62%	77.13%	100.94%	248.12%	234.97%	203.55%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.72	5.72	9.33	28.34	25.86	44.25	33.09	36.47	37.69	29.48	19.19	28.44
Quick Ratio	4.71	5.71	9.31	28.25	25.77	44.20	33.05	36.40	37.68	29.47	19.06	28.39
Working Capital	407.91M	501.88M	638.93M	712.64M	795.04M	846.45M	879.80M	910.96M	920.63M	933.56M	348.09M	367.90M
Leverage & Debt
Debt to Equity	0.28	0.21	0.12	0.04	0.04	0.02	0.03	0.03	0.03	0.04	0.06	0.04
Interest Coverage TTM	-22.27	-16.94	-11.67	-7.33	-5.16	-3.91	-3.69	-3.85	-4.45	-5.52	-6.71	-8.31
Debt Ratio	0.22	0.17	0.11	0.04	0.04	0.02	0.03	0.03	0.03	0.03	0.05	0.04
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-4.60	-4.09	-3.19	-2.11	-1.53	-1.14	-1.01	-0.89	-0.88	-0.91	-0.91	-0.81
Free Cash Flow Per Share TTM	-3.60	-2.94	-2.47	-2.00	-1.36	-1.20	-0.81	-0.67	-0.65	-0.53	-0.78	-0.67
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	211.75%	268.33%	227.05%	139.43%	77.32%	36.83%	28.02%	22.64%	30.58%	29.64%	24.73%	31.11%
EPS Growth (1Y)	200.68%	257.18%	216.52%	136.42%	74.56%	26.31%	10.77%	10.40%	17.12%	-1.82%	1.57%	0.46%
Valuation Metrics
P/E TTM	-8.48	-7.96	-11.02	-12.43	-17.32	-21.11	-39.90	-70.82	-60.49	-90.52	-20.44	-13.67
P/B TTM	11.11	7.49	6.20	4.14	3.74	3.20	4.98	7.70	6.35	9.08	5.04	3.00
Market Cap	4.54B	3.76B	3.96B	2.95B	2.97B	2.71B	4.39B	7.02B	5.85B	8.48B	1.76B	1.11B
Enterprise Value	4.41B	3.64B	3.80B	2.85B	2.94B	2.67B	4.36B	6.97B	5.81B	8.29B	1.70B	1.07B
Calculated Values
Free Cash Flow TTM	-418.44M	-340.33M	-278.69M	-224.58M	-152.54M	-133.99M	-87.79M	-74.25M	-71.95M	-54.87M	-73.38M	-66.66M
Net Debt	-125.75M	-118.12M	-165.81M	-100.38M	-33.88M	-37.94M	-26.68M	-50.35M	-43.92M	-195.58M	-55.52M	-37.19M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-10Purchase

Owner: Aubuchon, Neil William

Title: Chief Commercial Officer

Shares: 4,475

Price/Share: $33.50

Value: $149,912.50

Shares Owned: 4,475

Relationship: Officer

Ownership: Direct

2026-01-05Sale

Owner: Zante, Greg

Title: Chief Financial Officer

Shares: 57,661

Price/Share: $33.00

Value: $1,902,813.00

Shares Owned: 189,891

Relationship: Officer

Ownership: Direct

2026-01-05Sale

Owner: Lian, Brian

Title: President & CEO

Shares: 233,409

Price/Share: $33.74

Value: $7,875,219.66

Shares Owned: 2,499,291

Relationship: Director,Officer

Ownership: Direct

2026-01-05Sale

Owner: Mancini, Marianna

Title: Chief Operating Officer

Shares: 57,661

Price/Share: $33.74

Value: $1,945,482.14

Shares Owned: 409,190

Relationship: Officer

Ownership: Direct

2026-01-02Sale

Owner: Foehr, Matthew W

Title: -

Shares: 16,000

Price/Share: $35.11

Value: $561,760.00

Shares Owned: 132,036

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-10	Aubuchon, Neil William	Officer	Chief Commercial Officer	Direct	Purchase	4,475	33.50	$149,912.50	4,475	4
2026-01-05	Zante, Greg	Officer	Chief Financial Officer	Direct	Sale	57,661	33.00	$1,902,813.00	189,891	4
2026-01-05	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	233,409	33.74	$7,875,219.66	2,499,291	4
2026-01-05	Mancini, Marianna	Officer	Chief Operating Officer	Direct	Sale	57,661	33.74	$1,945,482.14	409,190	4
2026-01-02	Foehr, Matthew W	Director	-	Direct	Sale	16,000	35.11	$561,760.00	132,036	4
2025-10-28	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	38,989	35.01	$1,365,004.89	2,419,109	4
2025-10-28	Zante, Greg	Officer	Chief Financial Officer	Direct	Sale	6,185	35.00	$216,475.00	173,592	4
2025-10-28	Mancini, Marianna	Officer	Chief Operating Officer	Direct	Sale	6,185	35.00	$216,475.00	382,467	4
2025-10-27	Rowland, Charles A Jr	Director	-	Direct	Sale	60,000	35.57	$2,134,200.00	30,000	4
2025-07-03	Mancini, Marianna	Officer	Chief Operating Officer	Direct	Sale	4,266	27.77	$118,466.82	377,535	4
2025-07-03	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	26,889	27.80	$747,514.20	2,388,014	4
2025-07-03	Zante, Greg	Officer	Chief Financial Officer	Direct	Sale	4,266	27.76	$118,424.16	168,660	4
2025-03-31	Rouan, Sarah Kathryn	Director	-	Direct	Purchase	1,240	24.15	$29,946.00	1,240	4/A
2025-01-06	Zante, Greg	Officer	Chief Financial Officer	Direct	Sale	50,309	43.00	$2,163,287.00	165,259	4
2025-01-06	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	194,490	43.00	$8,363,070.00	2,366,570	4
2025-01-06	Mancini, Marianna	Officer	Chief Operating Officer	Direct	Sale	54,215	43.00	$2,331,245.00	374,134	4
2024-11-08	Macartney, Lawson	Director	-	Direct	Sale	2,000	68.67	$137,340.00	47,965	4
2024-10-28	Zante, Greg	Officer	Chief Financial Officer	Direct	Sale	131,687	78.19	$10,296,606.53	149,366	4
2024-10-25	Singleton, J Matthew	Director	-	Direct	Sale	16,000	79.50	$1,272,000.00	9,500	4
2024-10-25	Rouan, Sarah Kathryn	Director	-	Direct	Sale	11,000	80.89	$889,790.00	0	4
2024-09-20	Singleton, J Matthew	Director	-	Direct	Sale	10,300	69.50	$715,850.00	9,500	4
2024-09-20	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	216,130	71.19	$15,386,294.70	2,304,927	4
2024-08-21	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	1,000	69.90	$69,900.00	2,354,927	4
2024-08-21	Singleton, J Matthew	Director	-	Direct	Sale	5,700	69.72	$397,404.00	9,500	4
2024-08-19	Singleton, J Matthew	Director	-	Direct	Sale	16,000	62.52	$1,000,320.00	9,500	4
2024-08-19	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	112,870	66.27	$7,479,894.90	2,354,927	4
2024-08-14	Singleton, J Matthew	Director	-	Direct	Sale	20,786	57.94	$1,204,340.84	9,500	4
2024-07-30	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	115,859	57.85	$6,702,443.15	2,354,927	4
2024-07-30	Zante, Greg	Officer	Chief Financial Officer	Direct	Sale	16,136	57.79	$932,499.44	187,052	4
2024-07-30	Mancini, Marianna	Officer	Chief Operating Officer	Direct	Sale	18,026	57.40	$1,034,692.40	362,149	4
2024-05-03	Zante, Greg	Officer	Chief Financial Officer	Direct	Sale	66,756	74.87	$4,998,021.72	174,854	4
2024-05-01	Mancini, Marianna	Officer	Chief Operating Officer	Direct	Sale	281,425	78.38	$22,058,091.50	348,508	4
2024-02-09	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	45,000	29.90	$1,345,500.00	2,139,882	4
2024-02-08	Rouan, Sarah Kathryn	Director	-	Direct	Sale	25,000	28.05	$701,250.00	0	4
2024-02-08	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	269,079	27.00	$7,265,133.00	2,184,882	4
2024-01-31	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	85,000	24.70	$2,099,500.00	2,264,882	4
2024-01-30	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	35,000	23.95	$838,250.00	2,264,882	4
2024-01-19	Rouan, Sarah Kathryn	Director	-	Direct	Sale	30,000	23.05	$691,500.00	0	4
2024-01-04	Zante, Greg	Officer	Chief Financial Officer	Direct	Sale	15,000	17.90	$268,500.00	180,730	4
2023-05-16	Macartney, Lawson	Director	-	Direct	Sale	16,000	24.00	$384,000.00	47,965	4
2023-05-16	Rowland, Charles A Jr	Director	-	Direct	Sale	40,000	25.00	$1,000,000.00	30,000	4
2023-05-01	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	45,000	22.45	$1,010,250.00	2,197,963	4
2023-04-24	Macartney, Lawson	Director	-	Direct	Sale	16,000	22.00	$352,000.00	47,965	4
2023-04-19	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	35,000	21.45	$750,750.00	2,242,963	4
2023-04-17	Zante, Greg	Officer	Chief Financial Officer	Direct	Sale	7,500	20.00	$150,000.00	149,279	4
2023-04-17	Macartney, Lawson	Director	-	Direct	Sale	20,786	20.00	$415,720.00	47,965	4
2023-04-17	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	155,000	20.45	$3,169,750.00	2,277,963	4
2023-04-17	Mancini, Marianna	Officer	Chief Operating Officer	Direct	Sale	12,500	20.00	$250,000.00	287,763	4
2023-04-13	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	79,336	18.45	$1,463,749.20	2,307,963	4
2023-04-12	Zante, Greg	Officer	Chief Financial Officer	Direct	Sale	41,544	18.00	$747,792.00	149,279	4
2023-04-03	Lian, Brian	Director,Officer	President & CEO	Direct	Sale	22,000	17.85	$392,700.00	2,232,963	4
2023-04-03	Zante, Greg	Officer	Chief Financial Officer	Direct	Sale	30,911	18.00	$556,398.00	147,778	4
2023-03-29	Mancini, Marianna	Officer	Chief Operating Officer	Direct	Sale	41,242	16.00	$659,872.00	261,895	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

62.46%

Inst. Shares: 72,178,562

Shares Outstanding: 115,568,078

2025-12-31

63.35%

Inst. Shares: 71,375,870

Shares Outstanding: 112,667,303

2025-09-30

62.71%

Inst. Shares: 70,434,085

Shares Outstanding: 112,319,770

2025-06-30

66.36%

Inst. Shares: 74,417,363

Shares Outstanding: 112,134,425

2025-03-31

66.36%

Inst. Shares: 74,369,636

Shares Outstanding: 112,069,078

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	72,178,562	115,568,078	62.46%
2025-12-31	71,375,870	112,667,303	63.35%
2025-09-30	70,434,085	112,319,770	62.71%
2025-06-30	74,417,363	112,134,425	66.36%
2025-03-31	74,369,636	112,069,078	66.36%
2024-12-31	80,277,980	109,037,122	73.62%
2024-09-30	79,968,801	110,910,704	72.10%
2024-06-30	78,732,256	110,390,171	71.32%
2024-03-31	78,457,168	103,457,305	75.84%
2023-12-31	74,735,116	94,346,991	79.21%
2023-09-30	75,659,201	99,845,733	75.78%
2023-06-30	71,222,553	99,009,710	71.93%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Viking Therapeutics, Inc. (VKTX) — SEC Financial Statements & Analysis

Viking Therapeutics, Inc. (VKTX) is a pharmaceutical preparations company, incorporated in DE. Viking Therapeutics, Inc. trades on Nasdaq as: VKTX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Viking Therapeutics, Inc. reported a Debt-to-Equity ratio of 0.28x, a Price-to-Book (P/B) ratio of 11.11x (TTM), at a market cap of $4.54B. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.28x
P/B TTM: 11.11x
Market Cap: $4.54B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Viking Therapeutics, Inc. in?

Viking Therapeutics, Inc. (VKTX) operates in the Pharmaceutical Preparations industry.

What is VKTX's market cap?

Viking Therapeutics, Inc. (VKTX) has a market capitalization of $4.54B as of 2026-06-30.

What exchange does VKTX trade on?

Viking Therapeutics, Inc. (VKTX) trades on the Nasdaq.

Where is Viking Therapeutics, Inc. incorporated?

Viking Therapeutics, Inc. is incorporated in DE.